On a relative basis, the stock has outperformed the S&P 500 by 21.4% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.04% in the last 1 week, and is up 22.66% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 8.58% and the 50-Day Moving Average is 10.34%. Portola Pharmaceuticals (NASDAQ:PTLA): stock turned positive on Friday. Though the stock opened at $26.69, the bulls momentum made the stock top out at $27.89 level for the day. The stock recorded a low of $26.43 and closed the trading day at $27.61, in the green by 4.07%. The total traded volume for the day was 979,090. The stock had closed at $26.53 in the previous days trading.
The company Insiders own 8.7% of Portola Pharmaceuticals shares according to the proxy statements. Institutional Investors own 94.97% of Portola Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -23.64%. Also, Citigroup maintains their rating on the shares of Portola Pharmaceuticals (NASDAQ:PTLA). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $40 per share from $38 per share. The rating by the firm was issued on August 10, 2016.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.